Thus, inhibition of miR-182 and miR-144-5p might be important drug targets to find a new treatment for advanced phases of cancers where ANKRD36 has some role, including CML [61]. Here, ANKRD36 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.